Smart polymersome carriers for osteoporosis treatment: Enhanced bone regeneration via targeted teriparatide delivery

IF 4.6 2区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2026-01-01 Epub Date: 2025-12-18 DOI:10.1016/j.nano.2025.102891

Safoora Poorirani , Mina Mirian , Farshid Hassanzadeh , Ali N. Kamali , Adel Mohammadalipour , Mohammad Hashemnia , Sayed Abolfazl Mostafavi

{"title":"Smart polymersome carriers for osteoporosis treatment: Enhanced bone regeneration via targeted teriparatide delivery","authors":"Safoora Poorirani , Mina Mirian , Farshid Hassanzadeh , Ali N. Kamali , Adel Mohammadalipour , Mohammad Hashemnia , Sayed Abolfazl Mostafavi","doi":"10.1016/j.nano.2025.102891","DOIUrl":null,"url":null,"abstract":"<div><div>Targeted drug delivery improves therapeutic efficacy while minimizing off-target effects. In this study, PLGA-PEG-Su-Asp (PPSA) copolymers were synthesized to develop teriparatide-loaded nano-polymersomes (PPSA-PTH1-34 NP) for bone-targeted delivery. Nanoparticles were prepared by nanoprecipitation and optimized using a central composite design. The optimized nanoparticles had a size of 245.78 ± 8.2 nm, PDI of 0.352 ± 0.12, ZP of −18.89 ± 0.1 mV, and 72.20 ± 2.9 % drug entrapment efficiency. PPSA-PTH 1–34 exhibited strong affinity (64.86 %) to hydroxyapatite, enhancing targeting efficiency. <em>In vitro</em> assays in MG-63 cells confirmed time- and concentration-dependent proliferation, uptake efficiency, increased ALP activity, and mineralization. <em>In vivo</em> studies using an (ovariectomizd) OVX rat model showed that PPSA-PTH 1–34 significantly improved bone regeneration compared to free PTH1–34. These findings demonstrate that PPSA-based NP provide a promising platform for targeted and sustained PTH 1–34 delivery, potentially improving therapeutic outcomes in osteoporosis treatment.</div></div>","PeriodicalId":19050,"journal":{"name":"Nanomedicine : nanotechnology, biology, and medicine","volume":"71 ","pages":"Article 102891"},"PeriodicalIF":4.6000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine : nanotechnology, biology, and medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1549963425000929","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/18 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Targeted drug delivery improves therapeutic efficacy while minimizing off-target effects. In this study, PLGA-PEG-Su-Asp (PPSA) copolymers were synthesized to develop teriparatide-loaded nano-polymersomes (PPSA-PTH1-34 NP) for bone-targeted delivery. Nanoparticles were prepared by nanoprecipitation and optimized using a central composite design. The optimized nanoparticles had a size of 245.78 ± 8.2 nm, PDI of 0.352 ± 0.12, ZP of −18.89 ± 0.1 mV, and 72.20 ± 2.9 % drug entrapment efficiency. PPSA-PTH 1–34 exhibited strong affinity (64.86 %) to hydroxyapatite, enhancing targeting efficiency. In vitro assays in MG-63 cells confirmed time- and concentration-dependent proliferation, uptake efficiency, increased ALP activity, and mineralization. In vivo studies using an (ovariectomizd) OVX rat model showed that PPSA-PTH 1–34 significantly improved bone regeneration compared to free PTH1–34. These findings demonstrate that PPSA-based NP provide a promising platform for targeted and sustained PTH 1–34 delivery, potentially improving therapeutic outcomes in osteoporosis treatment.

Abstract Image

查看原文本刊更多论文

用于骨质疏松治疗的智能聚合体载体：通过靶向特立帕肽递送增强骨再生。

靶向给药提高了治疗效果，同时最大限度地减少了脱靶效应。在本研究中，合成了PLGA-PEG-Su-Asp （PPSA）共聚物，开发了用于骨靶向递送的三萜类肽负载纳米聚合体（PPSA- pth1 -34 NP）。采用纳米沉淀法制备纳米颗粒，并采用中心复合设计对其进行优化。优化纳米颗粒大小是245.78 ±8.2  nm, PDI 0.352 ± 0.12,ZP -18.89 ±0.1  mV,和72.20 ±2.9  %药物截留效率。PPSA-PTH 1-34对羟基磷灰石具有较强的亲和力（64.86 %），提高了靶向效率。MG-63细胞的体外实验证实了时间和浓度依赖性增殖、摄取效率、ALP活性增加和矿化。使用（去卵巢）OVX大鼠模型的体内研究表明，与游离PTH1-34相比，ppsa - PTH1-34显著改善骨再生。这些发现表明，基于ppsa的NP为靶向和持续递送PTH 1-34提供了一个有希望的平台，可能改善骨质疏松症治疗的治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nanomedicine : nanotechnology, biology, and medicine 工程技术-纳米科技

CiteScore

11.10

自引率

0.00%

发文量

133

审稿时长

42 days

期刊介绍： The mission of Nanomedicine: Nanotechnology, Biology, and Medicine (Nanomedicine: NBM) is to promote the emerging interdisciplinary field of nanomedicine. Nanomedicine: NBM is an international, peer-reviewed journal presenting novel, significant, and interdisciplinary theoretical and experimental results related to nanoscience and nanotechnology in the life and health sciences. Content includes basic, translational, and clinical research addressing diagnosis, treatment, monitoring, prediction, and prevention of diseases.